FLAT LAW FIRM
Request a consultation

Foreign Investment

EVFTA and Pharmaceuticals: Building a File That Survives Post-Clearance Verification

5 min readFLAT LAW FIRM

laboratory glassware, illustrating the pharmaceutical industry and testing
Illustration: laboratory glassware, illustrating the pharmaceutical industry and testing — source: Pexels (free to use).

A real-world scenario: A pharmaceutical company in Ho Chi Minh City exports finished medicines to the Netherlands, enjoying 0% EVFTA duty for two years. In year three, the importer reports: Dutch customs has requested post-clearance verification of 5 old consignments — suspecting that active pharmaceutical ingredients (APIs) imported from India do not meet origin rules. The company scrambles: batch records are fragmented, some two-year-old API invoices are missing, and nobody remembers who prepared the origin calculations. Result: unable to prove origin → preferences denied, duties recovered retroactively, and subsequent shipments scrutinized far more closely. This expensive lesson could have been avoided with the three-pillar file below.

1. Understanding post-clearance verification

When goods enter the EU under EVFTA preferential duty, the importing country’s customs may doubt and seek to verify the authenticity of origin documents — not only at clearance but after the goods have cleared, even years later. Verification runs through administrative cooperation: EU customs sends a request to Vietnam’s competent authority; Vietnam inspects the exporter, checks production records, and replies.

The key point: the burden of proof shifts to the exporter. Customs need not prove fraud — your failure to prove origin correctness is enough to deny preferences. And if systematic (not isolated) violations are found, preferences may be suspended for that exporter’s subsequent consignments.

2. Pillar one: keep records for at least 3 years — what, and who keeps them?

The EVFTA requires origin-related records to be kept for at least 3 years by all three actors: the exporter (origin evidence), the C/O issuing authority (issuance files), and the importing country’s customs (declarations). For a Vietnamese pharma business, “origin evidence” concretely means:

  • Origin calculations per product code: materials, origins, values, applicable rule;
  • Raw material purchase invoices (APIs, excipients, packaging) with suppliers’ origin evidence;
  • Bills of materials (BOM) and manufacturing processes;
  • Copies of issued EUR.1 certificates or issued origin declarations;
  • Export customs declarations and transport documents.

Note: 3 years is the treaty’s minimum — if Vietnamese law requires longer retention for accounting records, the longer period applies. And records must be retrievable per consignment, not a generic pile of paperwork.

3. Pillar two: pharma-specific traceability

Pharmaceuticals enjoy an advantage few industries have: GMP batch records already require lot-level traceability — from input materials (API batch numbers, suppliers, COAs) to finished output (medicine batch numbers, manufacturing dates). Smart businesses leverage the existing GMP system for origin proof instead of building a parallel paper trail.

What to add to existing batch records: origin information for APIs and excipients (country of manufacture, suppliers’ origin documents). Many pharma companies keep only the COA (certificate of analysis) without the API’s origin evidence — discovering the missing link only when verification hits. For APIs imported from India/China (common in the industry), the non-originating value ratio in the finished product’s ex-works price must be computed carefully from the origin-calculation stage.

4. Pillar three: a cooperation process when verification is requested

When a verification notice arrives (usually via the EU importer or directly from Vietnamese authorities), the business needs a ready response process:

  1. Single point of contact: designate one person/team to receive and coordinate — avoid each department answering differently.
  2. Deadlines: verification requests always carry reply deadlines. Keep a per-consignment file checklist ready for same-day retrieval — no warehouse “digging.”
  3. Data consistency: figures across origin calculations, batch records, invoices, and customs declarations must match. Cross-source discrepancies are a “red flag” inviting deeper probing.
  4. Do not alter records after a request: any edits or additions after receiving a verification request are viewed with suspicion. Files must be complete before inspection.

5. Contract clauses with the EU importer: do not carry the risk alone

Post-clearance verification risk legally falls on the importer (the preference beneficiary facing recovery), but commercially the importer will push all losses onto the exporter if the contract is silent. Three clauses to include:

  • Verification cooperation commitment: the exporter undertakes to supply documents within X days of a verification request;
  • Recovery risk allocation: agree who bears recovered duties and penalties if preferences are denied due to whose documentation fault;
  • Periodic audit right: allow the importer (or a third party) to audit the exporter’s origin documentation system annually — early detection costs far less than a customs finding.

The information in this article is general reference on the law as of the date of writing (18 October 2026) and does not replace legal advice for any specific case.

Frequently asked questions

1. How long after import can post-clearance verification occur?
Within the record-retention period (at least 3 years under the EVFTA). EU customs may request verification at any point in that window when grounds for doubt exist.

2. What must origin files contain?
Per-code origin calculations, raw material invoices (APIs, excipients, packaging) with suppliers’ origin evidence, BOMs, manufacturing processes, copies of C/Os or declarations, export customs declarations — retrievable per consignment.

3. What is pharma-specific about proving origin?
GMP batch records already provide lot traceability — just add API/excipient origin information (many firms keep only COAs, missing origin evidence). APIs from India/China need careful non-originating value ratio computation.

4. What happens if preferences are denied?
The importing country’s customs recovers duties at the (non-preferential) MFN rate plus penalties; systematic violations can trigger suspension of EVFTA preferences for the exporter’s subsequent consignments.

5. What is the EU importer’s role in verification?
They deal directly with EU customs and face duty recovery. Hence their strong incentive to demand Vietnamese exporter cooperation — and to shift losses onto Vietnam if the contract does not allocate risk clearly.

This article has been quality-reviewed by the FLAW AI Legal Council

Related articles